• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4602587)   Today's Articles (2338)   Subscriber (49368)
For: Clemons M, Verma S. Should oral bisphosphonates be standard of care in women with early breast cancer? Breast Cancer Res Treat 2005;90:315-8. [PMID: 15830146 DOI: 10.1007/s10549-004-4259-3] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Number Cited by Other Article(s)
1
Livi L, Scotti V, Desideri I, Saieva C, Cecchini S, Francolini G, Becherini C, Delli Paoli C, Visani L, Salvestrini V, De Feo ML, Nori J, Bernini M, Sanchez L, Orzalesi L, Bianchi S, Meattini I. Phase 2 placebo-controlled, single-blind trial to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: 5-year results of the single-centre BONADIUV trial. Eur J Cancer 2019;108:100-110. [DOI: 10.1016/j.ejca.2018.12.005] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2018] [Revised: 12/06/2018] [Accepted: 12/12/2018] [Indexed: 12/14/2022]
2
Eckert AW, Maurer P, Meyer L, Kriwalsky MS, Rohrberg R, Schneider D, Bilkenroth U, Schubert J. Bisphosphonate-related jaw necrosis--severe complication in maxillofacial surgery. Cancer Treat Rev 2006;33:58-63. [PMID: 17084033 DOI: 10.1016/j.ctrv.2006.09.003] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2006] [Revised: 08/31/2006] [Accepted: 09/01/2006] [Indexed: 11/24/2022]
3
Clemons MJ, Dranitsaris G, Ooi WS, Yogendran G, Sukovic T, Wong BYL, Verma S, Pritchard KI, Trudeau M, Cole DEC. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. J Clin Oncol 2006;24:4895-900. [PMID: 17001071 DOI: 10.1200/jco.2006.05.9212] [Citation(s) in RCA: 114] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
4
Santangelo A, Testai M, Barbagallo P, Manuele S, Di Stefano A, Tomarchio M, Trizzino G, Musumeci G, Panebianco P, Maugeri D. The use of bisphosphonates in palliative treatment of bone metastases in a terminally ill, oncological elderly population. Arch Gerontol Geriatr 2005;43:187-92. [PMID: 16325938 DOI: 10.1016/j.archger.2005.10.006] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2005] [Revised: 10/17/2005] [Accepted: 10/20/2005] [Indexed: 10/25/2022]
5
Gainford MC, Dranitsaris G, Clemons M. Recent developments in bisphosphonates for patients with metastatic breast cancer. BMJ 2005;330:769-73. [PMID: 15802719 PMCID: PMC555882 DOI: 10.1136/bmj.330.7494.769] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 01/29/2005] [Indexed: 11/04/2022]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA